Young Gyun Ko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Young Gyun Ko has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Hye Young Kim
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
7 shared publications - Doo Hyun Chung
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
6 shared publications - Jihyun Kim
Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
6 shared publications - Jongho Ham
Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
6 shared publications - TaeSoo Kim
Department of Life Science, Multitasking Macrophage Research Center, Ewha Womans University, Seoul, South Korea
6 shared publications - Sang-Jun Ha
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
4 shared publications
Latest Publications
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (124) , eadz0989
ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity
Innate lymphoid cells (ILCs) regulate tissue immunity, yet their roles in tumor control remain incompletely understood. Here, we combined analyses of human sequencing datasets with genetic ablation mouse models and adoptive transfer experiments to identify that glucocorticoid-induced tumor necrosis factor receptor (GITR) engagement on tumor-infiltrating group 2 ILCs (ILC2s) induced activating transcription factor 3 (ATF3) and robust interleukin-9 (IL-9) production, exceeding the modest coinduction of IL-5 and IL-13. ILC2-derived IL-9 promoted intratumoral eosinophil accumulation by enhancing survival, tissue retention, and cytotoxicity through tumor-induced IL-9 receptor expression. Eosinophil ablation abolished GITR-mediated tumor control, whereas adoptive eosinophil transfer restored it. This IL-9–eosinophil pathway suppressed tumor growth in the absence of adaptive lymphocytes. In human datasets, IL-9 and eosinophil signatures were associated with favorable prognosis in melanoma and lung adenocarcinoma. These findings define an innate pathway linking ILC2s to eosinophil-mediated tumor immunity and support GITR agonism as a therapeutic strategy.
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (124) , eadz0989
ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity
Innate lymphoid cells (ILCs) regulate tissue immunity, yet their roles in tumor control remain incompletely understood. Here, we combined analyses of human sequencing datasets with genetic ablation mouse models and adoptive transfer experiments to identify that glucocorticoid-induced tumor necrosis factor receptor (GITR) engagement on tumor-infiltrating group 2 ILCs (ILC2s) induced activating transcription factor 3 (ATF3) and robust interleukin-9 (IL-9) production, exceeding the modest coinduction of IL-5 and IL-13. ILC2-derived IL-9 promoted intratumoral eosinophil accumulation by enhancing survival, tissue retention, and cytotoxicity through tumor-induced IL-9 receptor expression. Eosinophil ablation abolished GITR-mediated tumor control, whereas adoptive eosinophil transfer restored it. This IL-9–eosinophil pathway suppressed tumor growth in the absence of adaptive lymphocytes. In human datasets, IL-9 and eosinophil signatures were associated with favorable prognosis in melanoma and lung adenocarcinoma. These findings define an innate pathway linking ILC2s to eosinophil-mediated tumor immunity and support GITR agonism as a therapeutic strategy.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary movie 1 from Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
Supplementary movie 1 from Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary movie 1 from Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
Supplementary movie 1 from Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
Type-2 innate lymphoid cells (ILC2) exhibit dual functions in cancer, both promoting and inhibiting tumor growth by regulating antitumor immune responses. Elucidation of the precise mechanisms by which ILCs regulate adaptive immune responses could support the development of improved immunotherapeutic approaches. In this study, we revealed that ILC2s possess the capacity to internalize, process, and present exogenous tumor antigen on MHC-I molecules, along with costimulatory molecules, to CD8+ T cells, thereby inducing their differentiation into CTLs. Transferring ILC2s into tumor-bearing mice resulted in CD8+ T-cell–dependent inhibition of tumor growth. Moreover, coculturing CD8+ T cells with ILC2s upregulated the expression of cytotoxic molecules, leading to efficient killing of cancer cells in vitro as well as in vivo upon transfer into tumor-bearing mice. Mechanistically, ILC2s employed clathrin-dependent endocytosis to internalize exogenous antigens and process/present them to CD8+ T cells as effectively as conventional antigen-presenting cells. Based on this study, ILC2s emerge as proficient antigen-presenting cells capable of stimulating the tumor-killing activity of CD8+ T cells, thus offering promising antitumor immunotherapeutic strategies.Significance:Type-2 innate lymphoid cells process and present tumor antigens to CD8+ T cells to increase cytotoxic activity against cancer cells, highlighting the potential to harness this intercellular interaction to improve cancer treatment.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
Type-2 innate lymphoid cells (ILC2) exhibit dual functions in cancer, both promoting and inhibiting tumor growth by regulating antitumor immune responses. Elucidation of the precise mechanisms by which ILCs regulate adaptive immune responses could support the development of improved immunotherapeutic approaches. In this study, we revealed that ILC2s possess the capacity to internalize, process, and present exogenous tumor antigen on MHC-I molecules, along with costimulatory molecules, to CD8+ T cells, thereby inducing their differentiation into CTLs. Transferring ILC2s into tumor-bearing mice resulted in CD8+ T-cell–dependent inhibition of tumor growth. Moreover, coculturing CD8+ T cells with ILC2s upregulated the expression of cytotoxic molecules, leading to efficient killing of cancer cells in vitro as well as in vivo upon transfer into tumor-bearing mice. Mechanistically, ILC2s employed clathrin-dependent endocytosis to internalize exogenous antigens and process/present them to CD8+ T cells as effectively as conventional antigen-presenting cells. Based on this study, ILC2s emerge as proficient antigen-presenting cells capable of stimulating the tumor-killing activity of CD8+ T cells, thus offering promising antitumor immunotherapeutic strategies.Significance:Type-2 innate lymphoid cells process and present tumor antigens to CD8+ T cells to increase cytotoxic activity against cancer cells, highlighting the potential to harness this intercellular interaction to improve cancer treatment.
- 17 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (14) , 2659-2678
Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
Type-2 innate lymphoid cells (ILC2) exhibit dual functions in cancer, both promoting and inhibiting tumor growth by regulating antitumor immune responses. Elucidation of the precise mechanisms by which ILCs regulate adaptive immune responses could support the development of improved immunotherapeutic approaches. In this study, we revealed that ILC2s possess the capacity to internalize, process, and present exogenous tumor antigen on MHC-I molecules, along with costimulatory molecules, to CD8+ T cells, thereby inducing their differentiation into CTLs. Transferring ILC2s into tumor-bearing mice resulted in CD8+ T-cell–dependent inhibition of tumor growth. Moreover, coculturing CD8+ T cells with ILC2s upregulated the expression of cytotoxic molecules, leading to efficient killing of cancer cells in vitro as well as in vivo upon transfer into tumor-bearing mice. Mechanistically, ILC2s employed clathrin-dependent endocytosis to internalize exogenous antigens and process/present them to CD8+ T cells as effectively as conventional antigen-presenting cells. Based on this study, ILC2s emerge as proficient antigen-presenting cells capable of stimulating the tumor-killing activity of CD8+ T cells, thus offering promising antitumor immunotherapeutic strategies. Significance: Type-2 innate lymphoid cells process and present tumor antigens to CD8+ T cells to increase cytotoxic activity against cancer cells, highlighting the potential to harness this intercellular interaction to improve cancer treatment.
- 17 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (14) , 2659-2678
Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
Type-2 innate lymphoid cells (ILC2) exhibit dual functions in cancer, both promoting and inhibiting tumor growth by regulating antitumor immune responses. Elucidation of the precise mechanisms by which ILCs regulate adaptive immune responses could support the development of improved immunotherapeutic approaches. In this study, we revealed that ILC2s possess the capacity to internalize, process, and present exogenous tumor antigen on MHC-I molecules, along with costimulatory molecules, to CD8+ T cells, thereby inducing their differentiation into CTLs. Transferring ILC2s into tumor-bearing mice resulted in CD8+ T-cell–dependent inhibition of tumor growth. Moreover, coculturing CD8+ T cells with ILC2s upregulated the expression of cytotoxic molecules, leading to efficient killing of cancer cells in vitro as well as in vivo upon transfer into tumor-bearing mice. Mechanistically, ILC2s employed clathrin-dependent endocytosis to internalize exogenous antigens and process/present them to CD8+ T cells as effectively as conventional antigen-presenting cells. Based on this study, ILC2s emerge as proficient antigen-presenting cells capable of stimulating the tumor-killing activity of CD8+ T cells, thus offering promising antitumor immunotherapeutic strategies. Significance: Type-2 innate lymphoid cells process and present tumor antigens to CD8+ T cells to increase cytotoxic activity against cancer cells, highlighting the potential to harness this intercellular interaction to improve cancer treatment.
- Open Access
- 1 January 2022
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 14 (4) , 361-378
The Dynamic Contribution of Neutrophils in the Chronic Respiratory Diseases
Ham J, et al. Allergy Asthma Immunol Res. 2022 Jul;14(4):361-378. https://doi.org/10.4168/aair.2022.14.4.361
- 1 January 2022
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 14 (4) , 361-378
Open AccessThe Dynamic Contribution of Neutrophils in the Chronic Respiratory Diseases
Ham J, et al. Allergy Asthma Immunol Res. 2022 Jul;14(4):361-378. https://doi.org/10.4168/aair.2022.14.4.361